Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries

Funding sources: PSONET was supported by funding from the European Academy of Dermatovenereology and the Italian Drug Agency (AIFA); the AMC psoriasis registry is funded by the Department of Dermatology of the Academic Medical Centre, the Netherlands; Australasian Psoriasis Registry was supported by unconditional funding from Epiderm, Abbott, Pfizer, Janssen‐Cilag, Merck‐Serono and MSD; BIOBADADERM was supported by unconditional funding from the Academia Española de Dermatología y Venereología, Agencia Española de Medicamentos y Productos Sanitarios, Abbott, Schering, MSD, Wyeth, Pfizer and Janssen‐Cilag; DERMBIO has received sponsoring from Abbott, Janssen‐Cilag, MSD and Pfizer; PSOBEST was supported by Abbott, MSD, Pfizer, Janssen‐Cilag, Biogen Idec and Medac; PSOCARE has been supported by AIFA. Conflicts of interest: I.G.‐D. has received congress grants from Pfizer, Janssen and MSD. T.N.D. is a consultant and/or speaker for Abbott, Janssen‐Cilag, LEO Pharma, MSD, Novo Nordisk and Pfizer. A.D.C. has received consultation fees from MSD and Abbott. C.B. has received research support from Epiderm, Abbott, Pfizer, Janssen‐Cilag, Merck‐Serono and MSD. P.I.S. is principal investigator in many pharmaceutical initiated trials in her department, has received departmental research support from MSD and attended advisory board meetings for Leo Pharma and Janssen. L.N. is a member of the scientific board of the PSOLAR registry which is supported by Centocor. The remaining authors have no conflicts of interest to declare.